Welcome to Kiadis Pharma

Kiadis Pharma is a clinical stage biopharmaceutical company developing innovative and potentially life-saving therapies for patients with late stage blood cancers and related disorders, an area of significant unmet medical need.

Kiadis Pharma’s products are based on hematopoietic (blood-forming) stem cell transplants from donors. Its lead product ATIR™ has the opportunity to expand the donor pool and improve outcomes for patients for whom matched sibling transplants or matched transplants from unrelated donors are not available. Currently, in many cases, these patients do not have access to a potentially curative treatment. In addition, ATIR™ is designed to facilitate rapid reconstitution of a new immune system in these patients without causing live threatening Graft versus Host Disease.

Kiadis Pharma’s mission is to become a leading provider of improved therapies to all transplant patients including those who receive hematopoietic (blood-forming) stem cell transplants from autologous (self) and allogeneic (non-self) donors including haploidentical transplants.

At the moment, Kiadis Pharma’s therapies are experimental in nature and are not yet commercially available. The company is collaborating with clinical centers in Europe and North America to further develop ATIR™.

Kiadis Pharma is based in Amsterdam, The Netherlands.
 

Kiadis Pharma Press Releases

Kiadis Pharma Press Releases
are available via an RSS feed. To add this RSS feed to your reader, right click on the RSS button, click "Copy Shortcut" and add the URL to your feed reader.